Placebo-controlled studies show that microdoses measurably change the brain and body, but so far they find few consistent improvements in mood or wellbeing beyond placebo. Surveys and personal reports are far more positive, and part of that gap is explained by expectation and by participants guessing what they took. Below you will find what the strongest studies show, why microdosing is so hard to measure, and what this means if you are considering microdosing.
What is a placebo-controlled microdosing study? A study that compares people taking a real microdose with people taking an identical-looking inactive capsule, without either group knowing which one they received. It is the most reliable way to separate the effect of a substance from the effect of expectation.
What do placebo-controlled studies say about microdosing?
The short answer: measurable effects, but no consistent benefits beyond placebo for mood, wellbeing or depression.
In September 2026, a systematic review in Frontiers in Psychiatry (Page et al.) analysed 11 studies on microdosing with psilocybin mushrooms and truffles, covering 3,262 adults. Eight studies reported at least one positive effect. But the two placebo-controlled trials found no significant improvements, and most studies did not report side effects at all. The authors conclude that current evidence is not enough to judge either effectiveness or safety.
A broader 2024 review by Polito and Liknaitzky looked at 19 placebo-controlled studies with LSD and psilocybin. Compared with placebo, microdoses did change brain activity, physiology, subjective experience, mood and cognition. However, results were mixed, many outcomes showed no difference, and several studies had a risk of bias. In other words: something happens in the body and brain, but that does not automatically translate into lasting benefits people can feel.
The key studies at a glance
| Study | Design | Participants | Main finding |
|---|---|---|---|
| Page et al., 2026, Frontiers in Psychiatry | Systematic review, psilocybin mushrooms and truffles | 11 studies, 3,262 adults | Positive reports in observational studies; the 2 placebo-controlled trials found no significant improvement |
| MindBio Phase 2b, 2026 (topline data, not yet peer-reviewed) | Triple-blind, active placebo (caffeine), LSD 4 to 20 µg, 8 weeks | 89 adults with major depression | LSD did not outperform placebo on depression scores |
| Prochazkova et al., 2025, Neuropharmacology | Double-blind, placebo-controlled, psilocybin | Healthy adults | No significant effect on behaviour or subjective measures compared with placebo |
| Polito and Liknaitzky, 2024, Journal of Psychopharmacology | Rapid review, LSD and psilocybin | 19 placebo-controlled studies | Measurable physiological and psychological changes, but mixed results and risk of bias |
| Cavanna et al., 2022, Translational Psychiatry | Double-blind, 0.5 g dried psilocybin mushrooms | 34 adults | Stronger effects than placebo only in people who correctly guessed they had taken the active dose |
| Murray et al., 2021, Psychopharmacology (University of Chicago) | Double-blind, placebo-controlled, single doses of 13 and 26 µg LSD | 22 healthy adults | Reduced brain wave power in default mode network regions, a pattern also seen at full doses; higher heart rate and blood pressure |
| Szigeti et al., 2021, eLife | Self-blinding citizen science, LSD or psilocybin | 191 adults | Wellbeing improved in both the microdose and the placebo group, with no significant difference |
| Ramaekers et al., 2020, Journal of Psychopharmacology (Maastricht University) | Double-blind, placebo-controlled, single doses of 5, 10 and 20 µg LSD | 24 healthy adults | At 20 µg, pain tolerance rose by about 20% compared with placebo |
| Hutten et al., 2020 (Maastricht University) | Placebo-controlled, single doses of 5, 10 and 20 µg LSD | Healthy adults | Higher blood levels of BDNF, a protein linked to neuroplasticity |
Why do surveys and personal reports look so much more positive?
There are four main reasons, and none of them means people are imagining things.
- Expectation shapes experience. When you expect to feel more focused or calmer, you often do. In the Szigeti study, how people felt was predicted better by what they thought they had taken than by what they actually took.
- Blinding breaks easily. A microdose is sometimes just noticeable. Once people suspect they took the real thing, expectation kicks in. In the Cavanna study, the active dose only stood out from placebo in participants who guessed correctly. Szigeti and colleagues showed in 2023 that this kind of broken blinding can create false positive results.
- Knowing changes the outcome. MindBio’s earlier open-label trial, in which everyone knew they were taking LSD, reported a 59.5% drop in depression scores. In the blinded follow-up trial, that effect disappeared. Note that MindBio has so far only shared topline results; the trial has not yet been peer-reviewed.
- Who takes part. Surveys mostly reach enthusiastic microdosers. People who stopped because it did nothing, or felt worse, are less likely to respond.
Dosing adds another layer. The 2026 review notes that no peer-reviewed definition of a truffle microdose exists; the authors had to rely on a threshold of 1 gram of fresh truffles taken from non-scientific sources. When doses vary this much between studies, comparing results is difficult.
Measurable effects: more than expectation alone?
Several placebo-controlled lab studies show that a microdose does something in the body that expectation alone does not easily explain.
Researchers at Maastricht University, working with the Beckley Foundation, gave healthy volunteers single doses of 5, 10 and 20 µg LSD or a placebo. At 20 µg, participants kept their hand in ice-cold water about 20% longer than on placebo and rated the pain as less intense. The same research programme found higher blood levels of BDNF, a protein linked to neuroplasticity, after low doses of LSD.
Maastricht researcher Kim Kuypers goes further. Speaking at the ICPR conference in Haarlem in 2022, in the VPRO radio documentary De Tripgeneratie, she said: “We do find effects on biological measures, so in my view it really isn’t placebo” (translated from Dutch). Her team also finds no effects on some measures where they expected them, such as creativity, and she stressed that what microdosing can mean for mental health care still has to be discovered. Earlier, she told WIRED that the BDNF increase “shows to me that something is happening”. At the same time, she has been clear that scientific proof of effectiveness is still lacking.
At the University of Chicago, Murray and colleagues found that 13 and 26 µg LSD reduced brain wave power in the default mode network, a pattern also seen at full psychedelic doses, and raised heart rate and blood pressure. Even there, most participants recognised the 26 µg dose, which shows how hard it is to keep a study blind.
These are mostly single doses of LSD in healthy volunteers, so they say little yet about repeated psilocybin microdosing in daily life. What they do show is that “just placebo” is too simple: a microdose is pharmacologically active.
So is microdosing just a placebo?
Based on current evidence, we cannot say that microdosing works better than placebo for mood, cognition or depression. We also cannot say for certain that it does not. Both statements matter.
The controlled trials so far are small and short. Most took place in labs with healthy volunteers and fixed doses, which is quite different from how people usually microdose: over months, with personal intentions, journaling and sometimes guidance. There is also an ongoing debate about the trial designs themselves. James Fadiman, for example, has pointed out that using caffeine as an active placebo in a depression trial is not a neutral comparison.
At the same time, the burden of proof lies with anyone who claims benefits. As long as well-controlled studies do not find a clear effect, honest communication means saying exactly that. What the research does show clearly is how strongly expectations, intention and context shape the outcome. That is one reason we put so much emphasis on clear intentions, honest self-observation and realistic expectations, rather than on promises.
Why microdosing is so hard to measure
I have helped with several of these studies myself, including the self-blinding study led by Balázs Szigeti and the psilocybin research by Prochazkova and colleagues. One thing all these researchers agree on: measuring the effects of microdosing is a real challenge. A lab can control the dose and the placebo, but microdosing is a practice that unfolds over weeks, with a dose that differs from person to person.
Kim Kuypers put it sharply at the same conference: “As scientists, we don’t have the right tools to do this research, in my view” (translated from Dutch). When a lab task finds no effect on creativity, she asked, is that because the substance does nothing, or because the task does not measure the creativity people actually mean?
The self-blinding study in particular raises questions every reader should know about. James Fadiman shared many of them:
- Nobody checked whether participants knew their own optimal dose. Sensitivity to psilocybin and LSD varies a lot between people, so the same amount can be too low for one person and clearly noticeable for another.
- Participants prepared their own doses and capsules at home. The actual amount in each capsule could not be verified.
- Only experienced microdosers could take part. Their answers may partly reflect what they remember and expect from earlier microdosing, rather than what they experienced that week.
- The study relied largely on online questionnaires. Self-reported measures are sensitive to expectation in both the microdose and the placebo group.
None of this makes the results worthless. It does mean that “no difference from placebo” should be read as “not shown under these conditions”, not as final proof that microdosing does nothing.
As I said in De Tripgeneratie: all of life is a placebo effect. You know what you are taking and why, and that expectation always shapes the outcome. That is exactly why set and setting matter, with plant and earth medicines at any dose.
What does this mean if you are considering microdosing?
- Keep your expectations realistic. Microdosing is not a proven treatment for any condition, and nobody can promise you results. For anxiety specifically, read what the evidence shows, and where it doesn’t.
- Observe yourself honestly. Keep a daily journal and note your mood and energy before you start. Some people even run their own blinded experiment, as in the Szigeti study.
- Take safety seriously. Do not combine microdosing with SSRIs, SNRIs, MAOIs or lithium without consulting your doctor, and never stop prescribed medication on your own. Microdosing is not advised during pregnancy or breastfeeding, or with a personal or family history of psychosis or bipolar disorder.
- Know the legal situation. In the Netherlands, fresh magic truffles are legal; psilocybin mushrooms and dried truffles are not. In many other countries, both are illegal, so check your local laws.
- Remember that side effects are under-researched. The 2026 review found that most studies did not track adverse events, and one study reported psychosis-like symptoms at higher doses.
Frequently asked questions
Is microdosing a placebo?
Not entirely. Placebo-controlled lab studies show that microdoses measurably affect the brain and body, for example pain tolerance and BDNF levels in studies at Maastricht University. Yet so far, no consistent improvement in mood, wellbeing or depression beyond placebo has been found.
How many placebo-controlled microdosing studies are there?
Around 19 placebo-controlled studies on LSD and psilocybin microdosing had been published by 2024. For psilocybin mushrooms and truffles specifically, a 2026 review found only two.
Why do so many people report benefits?
Expectation, broken blinding and the fact that surveys mainly reach enthusiastic users explain much of the difference. The positive experiences are real; what remains unclear is how much of them comes from the substance itself.
Does microdosing help with depression?
The best-controlled trial so far, MindBio’s Phase 2b study with 89 participants, found no benefit of LSD microdosing over placebo. These results have not yet been peer-reviewed. If you are dealing with depression, talk to your doctor or a mental health professional.
Is microdosing safe?
Short-term studies report mostly mild side effects, but long-term safety is unknown and side effects are poorly documented. Interactions with medication such as SSRIs, MAOIs and lithium are a real risk.
Explore microdosing with realistic expectations
Want to talk through whether microdosing makes sense for you, including the risks? Book an introductory call with one of our coaches.

